Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Efficacy of Sacituzumab Govitecan (SG) in Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

June 14th 2023

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBC

June 6th 2023

Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.

Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial Carcinoma

June 5th 2023

The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023

Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.

Dr Gupta on Anticipated Real-world Benefit of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

June 2nd 2023

Shilpa Gupta, MD, discusses the real-world benefit that may be derived based on findings from the long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial Carcinoma

May 31st 2023

Andrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma

Dr Katims on the Goal for Investigating the Immune Phenotype of FGFR3+ Upper Tract Urothelial Carcinoma

May 30th 2023

Andrew Katims, MD, MPH, discusses the rationale for investigating immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing.

Dr Grivas on Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer

May 24th 2023

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Dr Katims on Characterizing Immune Phenotype in FGFR3-mutated Upper Tract Urothelial Carcinoma

May 23rd 2023

Andrew Katims, MD, MPH, discusses research characterizing immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

As longer-term data read out for established regimens in urothelial cancer and up-and-coming therapeutics inch toward approval, optimizing treatment approaches relies on buy-in from multidisciplinary teams and patients.

Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer

May 19th 2023

Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.

Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

May 18th 2023

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC

May 18th 2023

Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

May 18th 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

May 18th 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

FDA Issues Complete Response Letter to BLA for N-803 in BCG-unresponsive NMIBC in Situ

May 11th 2023

The FDA has issued a complete response letter regarding the biologics license application for N-803 in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.

Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy

May 11th 2023

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma

May 11th 2023

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

Frontline Avelumab Maintenance Provides Prolonged Survival Benefit in Urothelial Carcinoma

May 10th 2023

Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

May 9th 2023

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.